Science & Enterprise subscription

Follow us on Twitter

  • A biotechnology company is developing modified immune system cells programmed to sense and respond to cancer cells… https://t.co/tLNPRr7ZOA
    about 11 hours ago
  • New post on Science and Enterprise: T-Cells Engineered to Release Anti-Cancer Proteins https://t.co/cnj0oCw5rv #Science #Business
    about 11 hours ago
  • An engineering team designed a process for adding and protecting tiny particles of nutrients in foods, boosting the… https://t.co/BodRPSI5g3
    about 13 hours ago
  • New post on Science and Enterprise: Polymer-Coated Microparticles Boost Food Nutrition https://t.co/rdGMQxPk5V #Science #Business
    about 13 hours ago
  • New contributed post on Science and Enterprise: https://t.co/ErXv6FGPSF How To Avoid Lapses In Productivity
    about 18 hours ago

Please share Science & Enterprise

Diagnostics Companies Get European Grant for Bladder Cancer

DNA strand (NSF)

(James. J. Caras, National Science Foundation)

Molecular diagnostics companies MDxHealth SA in Liege, Belgium and NovioGendix B.V. in Nijmegen, Netherlands have received a $1.1 million grant from Eurotrans-Bio to advance their bladder cancer program. NovioGendix is a spin-off company from Radboud University Nijmegen Medical Centre (RUNMC).

Eurotrans-Bio is a European Commission initiative to encourage cross-border research and development between small companies and academia working in the biotech industry. Jan Groen, CEO of MDxHealth says the funding provides the companies with “resources to investigate further the unique biological indicators and patterns seen in bladder cancer derived from patient samples from the existing collaboration of NovioGendix with RUNMC.”

MDxHealth and NovioGendix will apply the funds over the next two years to discover and validate biomarkers for the prediction of tumor progression into the muscle in developing invasive stage of bladder cancer. The companies expect to use DNA methylation technologies, DNA sequencing, and RNA-expression profiles on clinical samples collected from bladder cancer patients in the RUNMC urology department. Such predictive markers will guide treatment decisions for more aggressive bladder tumors.

Bladder cancer is one of the most common cancers, with 60 to 80 percent of survivors experiencing recurrence of the disease. National Cancer Institute reports more than 70,000 new cases of bladder cancer in the U.S. alone in 2010, with nearly 15,000 deaths.

Read more: Health System, Biotech Collaborate on Diagnostic Biomarkers

*     *     *

Please share Science & Enterprise ...
error

1 comment to Diagnostics Companies Get European Grant for Bladder Cancer